Lucero J, Alhumaid M, Novitzky-Basso I, Capo-Chichi JM, et al. Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation. Ann Hematol 2024;103:1187-1196.
PMID: 38291275